These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development. Parchment RE; Doroshow JH Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483 [TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic. Zhou Q; Gallo JM AAPS J; 2011 Mar; 13(1):111-20. PubMed ID: 21246315 [TBL] [Abstract][Full Text] [Related]
13. Translational PK/PD modeling to increase probability of success in drug discovery and early development. Lavé T; Caruso A; Parrott N; Walz A Drug Discov Today Technol; 2016; 21-22():27-34. PubMed ID: 27978984 [TBL] [Abstract][Full Text] [Related]
14. Current status and future perspective on preclinical pharmacokinetic and pharmacodynamic (PK/PD) analysis: Survey in Japan pharmaceutical manufacturers association (JPMA). Goto A; Abe S; Koshiba S; Yamaguchi K; Sato N; Kurahashi Y Drug Metab Pharmacokinet; 2019 Apr; 34(2):148-154. PubMed ID: 30827921 [TBL] [Abstract][Full Text] [Related]
15. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective. Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536 [TBL] [Abstract][Full Text] [Related]
16. Application of in vivo animal models to characterize the pharmacokinetic and pharmacodynamic properties of drug candidates in discovery settings. Amore BM; Gibbs JP; Emery MG Comb Chem High Throughput Screen; 2010 Feb; 13(2):207-18. PubMed ID: 20053166 [TBL] [Abstract][Full Text] [Related]
17. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps. Block M Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026 [TBL] [Abstract][Full Text] [Related]
18. Translational pharmacokinetic/pharmacodynamic analysis in cancer pharmacology: a tool to maximize the value of antitumor efficacy from tumor bearing mice. Wong H; Gould SE Drug Discov Today Technol; 2016; 21-22():51-56. PubMed ID: 27978988 [TBL] [Abstract][Full Text] [Related]
19. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Gieschke R; Steimer JL Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091 [TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase. Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]